Trihale Inhalation Capsule is a combination therapy containing Vilanterol Trifenatate 25 mcg, Fluticasone Furoate 200 mcg, and Umeclidinium Bromide 62.5 mcg. It is formulated for inhalation via a dry powder inhaler (DPI) and is primarily indicated for the management of chronic obstructive pulmonary disease (COPD) and severe asthma in adults.

This triple-combination therapy integrates three mechanisms:

1. Vilanterol Trifenatate: A long-acting β2-adrenergic agonist (LABA) that relaxes bronchial smooth muscle, providing bronchodilation and relief from airflow obstruction.

2. Fluticasone Furoate: An inhaled corticosteroid (ICS) that reduces airway inflammation, preventing exacerbations and improving lung function.

3. Umeclidinium Bromide: A long-acting muscarinic antagonist (LAMA) that blocks acetylcholine in the airways, promoting airway relaxation and reducing mucus production.

By combining these three agents, Trihale offers comprehensive control of symptoms, improved lung function, and reduced frequency of COPD and asthma exacerbations.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Trihale Inhalation Capsule is indicated for:

• Chronic Obstructive Pulmonary Disease (COPD): Long-term maintenance therapy to improve airflow and reduce exacerbations

• Severe asthma: For patients not adequately controlled with dual therapy (ICS + LABA)

• Prevention of exacerbations: Reduces frequency of hospitalizations and acute flare-ups

• Maintenance therapy: Suitable for patients requiring daily inhalation to maintain lung function

Trihale is not intended for acute symptom relief; a short-acting bronchodilator should be used for sudden breathing difficulties.

Mechanism of Action

The components of Trihale work synergistically to target multiple aspects of airway obstruction:

• Vilanterol Trifenatate (LABA): Stimulates β2 receptors in the lungs, relaxing smooth muscle and increasing airflow

• Fluticasone Furoate (ICS): Reduces airway inflammation by suppressing immune responses and preventing cytokine release

• Umeclidinium Bromide (LAMA): Blocks muscarinic receptors to inhibit bronchoconstriction and decrease mucus secretion

This triple mechanism improves breathing, reduces chronic inflammation, and maintains open airways over 24 hours with once-daily dosing.

Dosage and Administration

• Adult dose: 1 inhalation once daily via dry powder inhaler, at the same time each day

• Preparation: Open the capsule and place it in the inhaler device as instructed

• Inhalation: Inhale deeply and hold your breath for several seconds to ensure optimal deposition in the lungs

• Do not swallow the capsule; it is for inhalation only

• Consistency is key: Regular use ensures sustained symptom control and reduces exacerbation risk

Precautions and Warnings

• Not for acute attacks: Always keep a short-acting bronchodilator available for sudden symptoms

• Cardiovascular disease: Monitor patients with arrhythmias or hypertension, as LABA may affect heart rate

• Glaucoma and urinary retention: LAMA component may worsen these conditions

• Pregnancy and breastfeeding: Use only if clearly necessary under medical supervision

• Allergies: Avoid if hypersensitive to any component of the inhalation capsule'

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Side Effects

Trihale Inhalation Capsule is generally well tolerated. Possible side effects include:

• Headache, dizziness, or throat irritation

• Cough or hoarseness

• Dry mouth (due to LAMA component)

• Rare: palpitations, tremors, or hypersensitivity reactions

Most side effects are mild and manageable; report persistent or severe symptoms to a healthcare professional.

Storage

Store capsules in a cool, dry place below 30°C, protected from moisture and light. Keep out of reach of children.

Trihale Inhalation Capsule 25 mcg + 200 mcg + 62.5 mcg provides comprehensive, once-daily management of COPD and severe asthma, improving lung function, reducing inflammation, and minimizing exacerbations for enhanced respiratory health.